Novartis-owned Avidity Biosciences is currently evaluating del-brax in a recruiting Phase III study in FSHD.

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met ...

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and ...

Novartis said its RNA therapy del-brax met goals of a Phase 1/2 study in facioscapulohumeral muscular dystrophy (FSHD), an ...

Novartis AG NVS said Thursday that the biomarker cohort of its Phase 1/2 FORTITUDE study evaluating investigational therapy ...

NVS announces positive FORTITUDE data as del-brax met key endpoints, supporting its potential as a disease-modifying ...

Swiss pharma Novartis (NOVN: VX) said its investigational RNA therapy del-brax has met the primary and key secondary ...

Novartis ( (NVS)) has issued an update. On June 11, 2026, Novartis reported that the biomarker cohort of its FORTITUDE Phase I/II trial of delpacibart braxlosiran (del-brax) in facioscapulohumeral ...

New research has demonstrated that a combined regimen of growth hormone and testosterone is safe, well-tolerated, and is associated with meaningful improvements in muscle mass, strength, and mobility ...

Facioscapulohumeral muscular dystrophy (FSHD1A, OMIM#158900) is the third most common hereditary muscle disease after Duchenne muscular dystrophy and myotonic dystrophy, with an estimated prevalence ...

University of Iowa to use Bionano-based assay to replace most “gold standard” Southern blot tests for molecular diagnosis of FSHD SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.